Myriad Genetics (MYGN) EBIAT (2016 - 2025)
Myriad Genetics (MYGN) has disclosed EBIAT for 17 consecutive years, with -$7.9 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 81.41% to -$7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$365.9 million, a 187.43% decrease, with the full-year FY2025 number at -$365.9 million, down 187.43% from a year prior.
- EBIAT was -$7.9 million for Q4 2025 at Myriad Genetics, up from -$27.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $24.6 million in Q3 2021 to a low of -$330.5 million in Q2 2025.
- A 5-year average of -$44.8 million and a median of -$29.3 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: soared 261.84% in 2021, then crashed 800.54% in 2025.
- Myriad Genetics' EBIAT stood at -$7.6 million in 2021, then tumbled by 456.58% to -$42.3 million in 2022, then grew by 26.24% to -$31.2 million in 2023, then crashed by 36.22% to -$42.5 million in 2024, then skyrocketed by 81.41% to -$7.9 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's EBIAT are -$7.9 million (Q4 2025), -$27.4 million (Q3 2025), and -$330.5 million (Q2 2025).